Synergistic Effects of PI3K and c-Myc Co-targeting in Acute Leukemia: Shedding New Light on Resistance to Selective PI3K-δ Inhibitor CAL-101
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Synergistic Effects of PI3K and c-Myc Co-targeting in Acute Leukemia: Shedding New Light on Resistance to Selective PI3K-δ Inhibitor CAL-101
Authors
Keywords
-
Journal
CANCER INVESTIGATION
Volume 37, Issue 7, Pages 311-324
Publisher
Informa UK Limited
Online
2019-08-15
DOI
10.1080/07357907.2019.1651328
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Small molecule inhibitor of c-Myc 10058-F4 inhibits proliferation and induces apoptosis in acute leukemia cells, irrespective of PTEN status
- (2019) Davood Bashash et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- CIP2A facilitates the G1/S cell cycle transition via B-Myb in human papillomavirus 16 oncoprotein E6-expressing cells
- (2018) Yonghao Tian et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Prognostic significance of CIP2A expression in solid tumors: A meta-analysis
- (2018) Min Tang et al. PLoS One
- Inhibition of PI3K signaling pathway enhances the chemosensitivity of APL cells to ATO: Proposing novel therapeutic potential for BKM120
- (2018) Davood Bashash et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Anti-tumor activity of PI3K-δ inhibitor in hematologic malignant cells: Shedding new light on resistance to Idelalisib
- (2017) Davood Bashash et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Telomerase and mTOR in the brain: the mitochondria connection
- (2017) Gabriele Saretzki et al. Neural Regeneration Research
- PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
- (2017) Anella Yahiaoui et al. PLoS One
- Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells
- (2017) Ming Zhao et al. Oncotarget
- Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: Shedding new light on NVP-BKM120 mechanism of action
- (2016) Davood Bashash et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Concomitant reduction of c-Myc expression and PI3K/AKT/mTOR signaling by quercetin induces a strong cytotoxic effect against Burkitt’s lymphoma
- (2016) Marisa Granato et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- PI3K inhibitors as new cancer therapeutics: implications for clinical trial design
- (2016) Cristian Massacesi et al. OncoTargets and Therapy
- Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells
- (2016) Chun-Yu Liu et al. Oncotarget
- Small-molecule inhibitors of the Myc oncoprotein
- (2015) Steven Fletcher et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice
- (2015) Yinfei Tan et al. CANCER BIOLOGY & THERAPY
- c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia
- (2015) Bing Xia et al. LEUKEMIA RESEARCH
- AML drug resistance: c-Myc comes into play
- (2014) C. Fauriat et al. BLOOD
- Inhibition of c-Myc Overcomes Cytotoxic Drug Resistance in Acute Myeloid Leukemia Cells by Promoting Differentiation
- (2014) Xiao-Na Pan et al. PLoS One
- BIBR 1532 Increases Arsenic Trioxide-mediated Apoptosis in Acute Promyelocytic Leukemia Cells: Therapeutic Potential for APL
- (2013) Davood Bashash et al. Anti-Cancer Agents in Medicinal Chemistry
- Myc inhibition impairs autophagosome formation
- (2013) Pearl P. C. Toh et al. HUMAN MOLECULAR GENETICS
- Addiction to c-MYC in multiple myeloma
- (2012) T. Holien et al. BLOOD
- MYC on the Path to Cancer
- (2012) Chi V. Dang CELL
- An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
- (2012) L. A. Byers et al. CLINICAL CANCER RESEARCH
- PI3K signalling: the path to discovery and understanding
- (2012) Bart Vanhaesebroeck et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies
- (2011) Jorge J Castillo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer
- (2011) Markus K Muellner et al. Nature Chemical Biology
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
- (2010) S. E. M. Herman et al. BLOOD
- Autophagy in cancer associated fibroblasts promotes tumor cell survival
- (2010) Ubaldo E. Martinez-Outschoorn et al. CELL CYCLE
- Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia
- (2009) Alberto M Martelli et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia
- (2009) S. Park et al. HAEMATOLOGICA
- Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc–Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice
- (2008) Jianxia Guo et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation